000099180 001__ 99180
000099180 005__ 20230519145403.0
000099180 0247_ $$2doi$$a10.3390/antibiotics10010013
000099180 0248_ $$2sideral$$a122680
000099180 037__ $$aART-2021-122680
000099180 041__ $$aeng
000099180 100__ $$aCaldas, M.
000099180 245__ $$aEuropean registry on helicobacter pylori management: Effectiveness of first and second-line treatment in Spain
000099180 260__ $$c2021
000099180 5060_ $$aAccess copy available to the general public$$fUnrestricted
000099180 5203_ $$aThe management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. pylori treatment in Spain, where the empirical prescription is recommended. A multicentre prospective non-interventional registry of the clinical practice of European gastroenterologists concerning H. pylori infection (Hp-EuReg) was developed, including patients from 2013 until June 2019. Effectiveness was evaluated descriptively and through a multivariate analysis concerning age, gender, presence of ulcer, proton-pump in-hibitor (PPI) dose, therapy duration and compliance. Overall, 53 Spanish hospitals were included, and 10, 267 patients received a first-line therapy. The best results were obtained with the 10-day bismuth single-capsule therapy (95% cure rate by intention-to-treat) and with both the 14-day bismuth-clarithromycin quadruple (PPI-bismuth-clarithromycin-amoxicillin, 91%) and the 14-day non-bismuth quadruple concomitant (PPI-clarithromycin-amoxicillin-metronidazole, 92%) therapies. Second-line therapies were prescribed to 2448 patients, with most-effective therapies being the triple quinolone (PPI-amoxicillin-levofloxacin/moxifloxacin) and the bismuth-levofloxacin quadruple schemes (PPI-bismuth-levofloxacin-amoxicillin) prescribed for 14 days (92%, 89% and 90% effective-ness, respectively), and the bismuth single-capsule (10 days, 88.5%). Compliance, longer duration and higher acid inhibition were associated with higher effectiveness. “Optimized” H. pylori therapies achieve over 90% success in Spain.
000099180 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000099180 590__ $$a5.222$$b2021
000099180 592__ $$a0.785$$b2021
000099180 594__ $$a3.9$$b2021
000099180 591__ $$aPHARMACOLOGY & PHARMACY$$b68 / 279 = 0.244$$c2021$$dQ1$$eT1
000099180 593__ $$aBiochemistry$$c2021$$dQ1
000099180 591__ $$aINFECTIOUS DISEASES$$b39 / 96 = 0.406$$c2021$$dQ2$$eT2
000099180 593__ $$aMicrobiology$$c2021$$dQ1
000099180 593__ $$aPharmacology, Toxicology and Pharmaceutics (miscellaneous)$$c2021$$dQ1
000099180 593__ $$aPharmacology (medical)$$c2021$$dQ1
000099180 593__ $$aMicrobiology (medical)$$c2021$$dQ1
000099180 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000099180 700__ $$aPérez-Aisa, Á.
000099180 700__ $$aCastro-Fernández, M.
000099180 700__ $$aBujanda, L.
000099180 700__ $$aLucendo, A.J.
000099180 700__ $$aRodrigo, L.
000099180 700__ $$aHuguet, J.M.
000099180 700__ $$aPérez-Lasala, J.
000099180 700__ $$aMolina-Infante, J.
000099180 700__ $$aBarrio, J.
000099180 700__ $$aFernández-Salazar, L.
000099180 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, Á.$$uUniversidad de Zaragoza
000099180 700__ $$aPerona, M.
000099180 700__ $$aDomínguez-Cajal, M.
000099180 700__ $$aOrtuño, J.
000099180 700__ $$aGómez-Rodríguez, B.J.
000099180 700__ $$aAlmela, P.
000099180 700__ $$aBotargués, J.M.
000099180 700__ $$aNúñez, Ó.
000099180 700__ $$aModolell, I.
000099180 700__ $$aGómez, J.
000099180 700__ $$aRuiz-Zorrilla, R.
000099180 700__ $$aDe la Coba, C.
000099180 700__ $$aHuerta, A.
000099180 700__ $$aIyo, E.
000099180 700__ $$aPozzati, L.
000099180 700__ $$aAntón, R.
000099180 700__ $$aBarenys, M.
000099180 700__ $$aAngueira, T.
000099180 700__ $$aFernández-Bermejo, M.
000099180 700__ $$aCampillo, A.
000099180 700__ $$aAlcedo, J.
000099180 700__ $$aPajares-Villaroya, R.
000099180 700__ $$aMego, M.
000099180 700__ $$aBermejo, F.
000099180 700__ $$aDominguez-Jiménez, J.L.
000099180 700__ $$aTitó, L.
000099180 700__ $$aFernández, N.
000099180 700__ $$aPabón-Carrasco, M.
000099180 700__ $$aCosme, Á.
000099180 700__ $$aMata-Romero, P.
000099180 700__ $$aAlcaide, N.
000099180 700__ $$aAriño, I.
000099180 700__ $$aDi Maira, T.
000099180 700__ $$aGarre, A.
000099180 700__ $$aPuig, I.
000099180 700__ $$aNyssen, O.P.
000099180 700__ $$aMegraud, F.
000099180 700__ $$aO’morain, C.
000099180 700__ $$aGisbert, J.P.
000099180 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000099180 773__ $$g10, 1 (2021), 13 [15 pp]$$pAntibiotics$$tAntibiotics$$x2079-6382
000099180 8564_ $$s465070$$uhttps://zaguan.unizar.es/record/99180/files/texto_completo.pdf$$yVersión publicada
000099180 8564_ $$s3089401$$uhttps://zaguan.unizar.es/record/99180/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000099180 909CO $$ooai:zaguan.unizar.es:99180$$particulos$$pdriver
000099180 951__ $$a2023-05-18-13:43:05
000099180 980__ $$aARTICLE